Latest News and Press Releases
Want to stay updated on the latest news?
-
LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aerovironment, Inc., (“Aerovironment" or the "Company") (NASDAQ: AVAV) investors that the firm has initiated an...
-
Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regencell Bioscience Holdings Limited, (“Regencell” or the "Company") (NASDAQ: RGC) investors of a class action on behalf...
-
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics, Inc., (“Galectin" or the "Company") (NASDAQ: GALT) investors that the firm has initiated an...
-
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises New Era Energy & Digital, Inc., (“New Era” or the "Company") (NASDAQ: NUAI) investors of a class action on behalf of...
-
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Power Solutions International, Inc., (“Power Solutions" or the "Company") (NASDAQ:PSIX) investors that the firm has...
-
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Pinterest, Inc., (“Pinterest” or the "Company") (NYSE: PINS) investors of a class action on behalf of investors that...
-
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Atara Biotherapeutics, Inc., (“Atara” or the "Company") (NASDAQ: ATRA) investors of a class action on behalf of investors...
-
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Concorde International Group, Ltd., (“Concord” or the "Company") (NASDAQ:CIGL) investors of a class action on behalf of...
-
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Gartner, Inc., (“Gartner” or the “Company”) (NYSE:IT) investors off a class action on behalf of investors that bought...
-
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aldeyra Therapeutics, Inc., (“Aldeyra” or the "Company") (NASDAQ: ALDX) investors of a class action on behalf of...